The Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts

News provided by

Bharat Book Bureau

20 Feb, 2015, 15:30 GMT

MUMBAI, February 20, 2015 /PRNewswire/ --

A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights.

Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs.

The "Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.

To order this report and request for sample page: 

https://www.bharatbook.com/drugs-market-research-reports-640930/generic-drugs-market-opportunities-challenges-strategies-forecasts.html

Key Findings: 

  • Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years.
  • As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan.
  • In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs.
  • In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia.
  • Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020.

Topics Covered: 

  • Generic drugs ecosystem
  • Market drivers and barriers
  • Technology, economics and key trends
  • Pure, branded and super generics
  • Analysis of key therapeutic areas and leading generic drugs
  • Regulatory landscape of generic drugs throughout the globe
  • Industry roadmap and value chain
  • Profiles and strategies of over 130 leading ecosystem players, including generic and innovator drug manufacturers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2015 till 2030

Historical Revenue & Forecast Segmentation: 

Market forecasts are provided for each of the following submarkets and their subcategories: 

Brand Classification 

- Pure (Non-branded) Generics

- Branded Generics

- Super Generics

Therapeutic Area 

- Antibiotics

- Cardiovascular & Hypertension

- CNS (Central Nervous System)

- Dermatology

- Diabetes

- Gastrointestinal

- Hormonal Drugs

- Oncology

- Pain Relief

- Respiratory

- Rheumatology

- Others

Regional Markets 

- Asia Pacific

- Europe

- Middle East & Africa

- North America

- Latin & Central America

Country Markets 

- Brazil

- Canada

- China

- Egypt

- France

- Germany

- Greece

- India

- Israel

- Italy

- Japan

- Mexico

- Netherlands

- Poland

- Portugal

- Russia

- Saudi Arabia

- South Africa

- South Korea

- Spain

- Switzerland

- Taiwan

- Turkey

- UK

- USA

Table of Content 

  • Chapter 1: Introduction 14
  • Chapter 2: An Overview of Generic Drugs 26
  • Chapter 3: Regulatory Landscape 35
  • Chapter 4: Drug Class Availability & Leading Therapies 43
  • Chapter 5: Generic Drugs Industry Roadmap & Value Chain 60
  • Chapter 6: Key Market Players 65
  • Chapter 7: Market Analysis & Forecasts 204
  • Chapter 8: Conclusion & Strategic Recommendations 242

Companies Covered: 

- Abbott Laboratories

- AbbVie

- ACETO Corporation

- Acino Holding

- Actavis

- Baxter BioScience

- Baxter International

- Bayer AG

- BD (Becton

- Dickinson and Company)

- Cadila Healthcare (Zydus Cadila)

- Cadila Pharmaceuticals

- CBER (Centre for Biologics Evaluation and Research)

- CDER (Centre for Drug Evaluation and Research)

- CDSCO (Central Drug Standards and Control Organization - India)

- Daiichi Sankyo

- Daiichi Sankyo Espha

- Dong-A Pharmaceutical

- Dr. Reddy's Laboratories

- Dusa Pharmaceuticals

- EGA (European Generic Medicines Association)

- Egis Pharmaceuticals

- Eisai Company

- Eli Lilly and Company

- Elmed Eisai Company

- FDA (Food and Drug Administration)

- Ferring Pharmaceuticals

- Forest Laboratories

- Fresenius Kabi

- Fuji Pharma Company

- Galderma

- Galenika

- Gedeon Richter

- Gedeon Richter PregLem

- Genepharm

- Hanmi Pharmaceutical Company

- Health Canada

- Hetero Drugs

- Hikma Pharmaceuticals

- Hi-Tech Pharmacal

- Impax Laboratories

- Impax Pharmaceuticals

- Ipsen

- Janssen Pharmaceutica

- Jazz Pharmaceuticals

- JHP Group Holdings

- JHP Pharmaceuticals

- Johnson & Johnson

- Kaken Pharmaceutical Company

- Kaneka Corporation

- Kowa Company

- Kowa Health Care America

- Kowa Pharmaceuticals America

- Laboratorios Roemmers

- Leo Pharma

- Les Laboratoires Servier

- Lil Therapeutics

- Lundbeck (H. Lundbeck A/S)

- Mallinckrodt

- Maruho Company

- Matrix Laboratories

- Meda

- Medley Farma

- Labour and Welfare (Japan)

- Natco Pharma

- Nichi-Iko Pharmaceutical Company

- Nippon Kayaku

- Nippon Shinyaku

- Nipro Pharma Corporation

- OLIC (Thailand)

- Ono Pharmaceutical Company

- Orion Corporation

- Osaka Synthetic Chemical Laboratories

- Otsuka Holdings Company

- Pfizer

- Pharma Dynamics

- Pharmstandard

- Pierre Fabre (Laboratoires Pierre Fabre)

- Piramal Enterprises

- Qualitest and Vintage Pharmaceuticals

- Ranbaxy Laboratories

- Recordati

- Regeneron Pharmaceuticals

- Rising Pharmaceuticals

- Roche Holding (F. Hoffmann-La Roche)

- Shionogi & Company

- Shire

- Sigma-Tau

- Somar (Grupo Farmaceutico Somar)

- STADA Arzneimittel

- Teva-Kowa Pharma Company

- The Medicines Company

- Torrent Group

- UCB

- United Therapeutics Corporation

- Valeant Pharmaceuticals International

- Ventana Medical Systems

- Vertex Pharmaceuticals

- Warner-Chilcott

- West-Ward Pharmaceuticals

- WHO (World Health Organization)

- Wockhardt

- Zentiva

Related Reports 

About Bharat Book Bureau 

Bharat Book Bureau is the leading market research information aggregator that provides market research reports, industry analysis, company profiles, business reports, country reports, newsletters and online databases. Our clients include Corporate, Consulting firms, and Academic Institutions and Government departments across the globe. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. The market research reports we provide, help global companies examine the different markets before setting up a business or expanding into different countries across the world. They give a complete perspective on the current market scenario, trends, segments and future outlook.

Blog: https://www.bharatbook.com/blog/

W: https://www.bharatbook.com/

Contact Details:
Poonam
Bharat Book Bureau
India: +91-22-27810772, 27810773
E-mail: poonam@bharatbook.com